Prenatal treatment path for angelman syndrome and other neurodevelopmental disorders.
Prenatal gene testing plus newborn behavior checks could let us treat Angelman syndrome before symptoms pile up.
01Research in Context
What this study did
Bradley (2020) wrote a position paper. It says we can start treating Angelman syndrome before birth.
Doctors would use prenatal gene tests plus baby behavior checks in the first months. The goal is to stop or soften symptoms before they show.
What they found
The paper does not give new data. It maps a future path: test genes early, watch behavior early, treat early.
How this fits with other research
Giallo et al. (2006) laid the groundwork. That paper explained how imprinting errors cause Angelman learning problems. Bradley (2020) takes the same imprinting idea and asks, "What if we act on it before birth?"
Goulardins et al. (2013) looked at Rett syndrome babies. They found speech delays long before the big regression. Bradley (2020) makes a similar bet: Angelman babies already show tiny clues soon after birth. Together, the two papers push you to watch infants closer, no matter the label.
Kittler et al. (2004) warned that many adults still lack a final diagnosis. Bradley (2020) flips the timeline: start the gene hunt prenatally so families never reach that late-diagnosis dead end.
Why it matters
You may not give prenatal care, but you often see babies flagged for delay. Knowing Angelman can be spotted and maybe treated ultra-early tells you to push for speedy genetic work-up and tight developmental tracking. The sooner the label is clear, the sooner you can start high-quality ABA and parent coaching.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add Angelman syndrome to your infant red-flag list and refer for genetics if floppy tone plus no babbling appear before 6 months.
02At a glance
03Original abstract
Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by mutation or deletion of the maternally inherited UBE3A allele. These pathogenic mutations lead to loss of maternal UBE3A expression in neurons. Antisense oligonucleotides and gene therapies are in development, which activate the intact but epigenetically silenced paternal UBE3A allele. Preclinical studies indicate that treating during the prenatal period could greatly reduce the severity of symptoms or prevent AS from developing. Genetic tests can detect the chromosome 15q11-q13 deletion that is the most common cause of AS. New, highly sensitive noninvasive prenatal tests that take advantage of single-cell genome sequencing technologies are expected to enter the clinic in the coming years and make early genetic diagnosis of AS more common. Efforts are needed to identify fetuses and newborns with maternal 15q11-q13 deletions and to phenotype these babies relative to neurotypical controls. Clinical and parent observations suggest AS symptoms are detectable in infants, including reports of problems with feeding and motor function. Quantitative phenotypes in the 0- to 1-year age range will permit a more rapid assessment of efficacy when future treatments are administered prenatally or shortly after birth. Although prenatal therapies are currently not available for AS, prenatal testing combined with prenatal treatment has the potential to revolutionize how clinicians detect and treat babies before they are symptomatic. This pioneering prenatal treatment path for AS will lay the foundation for treating other syndromic neurodevelopmental disorders. Autism Res 2020, 13: 11-17. © 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Prenatal treatment could benefit expectant parents whose babies test positive for the chromosome microdeletion that causes Angelman syndrome (AS). Prenatal treatment is predicted to have better outcomes than treating after symptoms develop and may even prevent AS altogether. This approach could generally be applied to the treatment of other syndromic neurodevelopmental disorders.
Autism research : official journal of the International Society for Autism Research, 2020 · doi:10.1523/JNEUROSCI.5746-12.2013